NIH Turned Down Investigators Who Provoked Ire From Alcohol Industry

An email exchange and an unusual meeting suggest a connection between an institute’s pursuit of industry support and the rejection of a grant application.

Apr 3, 2018
Shawna Williams

ISTOCK, KATARZYNABIALASIEWICZA research funding request to the National Institutes of Health (NIH) may have been quashed as part of an effort to woo industry sponsors of another large study, reports STAT News. The evidence includes an email exchange between the director of the National Institute of Alcohol Abuse and Alcoholism (NIAAA) and an alcohol company executive pledging not to fund the type of study that linked alcohol advertising to teen drinking.

The news report builds on earlier revelations by Wired and The New York Times that NIAAA scientists courted industry funders of a study on the health effects of moderate alcohol consumption by emphasizing the probability that the results would favor such consumption. STAT adds fresh evidence that conflicts of interest may have influenced decisions at the National Institutes of Health (NIH), the largest federal funder of biomedical research.

In the article published by STAT yesterday (April 2), Michael Siegel, a community health researcher at Boston University School of Public Health, gives an account of a 2015 meeting in which he and a coinvestigator on an NIAAA-funded study were summoned to the institute to discuss the work. In the meeting, George Koob, the NIAAA Director, “kept trying to downplay the importance of this research, insisting it was not advertising that made teenagers drink but peer pressure and parents. He was giving us the industry line,” Siegel tells STAT. A new proposal by the coinvestigator to study social media activity by alcohol companies was rejected soon afterward, despite receiving high marks from reviewers.

As it turned out, months after assuming the NIAAA directorship in 2014, Koob had written an email to Samir Zakhari of the Distilled Spirits Council, STAT found, promising that research like Siegel’s advertising project would not be funded again. Zakhari thanked Koob, responding in part, “This kind of research not only wastes precious research dollars but also damages NIAAA’s stature within the NIH community.” In an email to STAT, Koob stated his exchange with Zakhari “was to convey that I had no intention of supporting research that was not of the highest scientific quality.”

In October 2017, Wired reported that for the first time, the alcohol industry was expected to partially sponsor an NIH study, in which thousands of participants would be randomly assigned to either have an alcoholic drink of their choice each day for six years (its cost reimbursed by the investigators), or to abstain. Their health outcomes and mortality rates would be tracked. At the time, five alcohol corporations had pitched in a total of $67 million for the project. Koob and Peggy Murray, who directs the institute’s Global Alcohol Research Program, had both appeared in an Anheuser-Busch InBev video promoting the company’s sponsorship of research.

Then, last month, The New York Times reported that NIAAA had “waged a vigorous campaign to court the alcohol industry.” One slide from the agency presented to an industry audience states, “A definitive clinical trial represents a unique opportunity to show that moderate alcohol consumption is safe and lowers risk of common diseases.”

Siegel, who reviewed the presentation, told the Times that the study “is not public health research—it’s marketing. . . . They’re admitting the trial is designed to provide a justification for moderate drinking. That’s not objective science.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.